Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • The Pharma 50

Moderna shares R&D updates at third annual vaccines day

By Brian Buntz | March 24, 2022

ModernaModerna (Nasdaq:MRNA) recently announced that an investigational version of its COVID-19 vaccine for potential use in children 6 months to 6 years met its primary endpoint in a Phase 2/3 study. Two doses of the vaccine were 43.7% effective at preventing infection during the omicron wave in children aged 6 months to 2 years old. Efficacy fell to 37.5% in children aged 2 to 6.

As part of a series of Vaccine Day–themed announcements, the company said it is making progress with global regulatory submissions for the mRNA-1273 in younger children. The company hopes to receive authorization for a 25 μg two-dose primary series of the COVID-19 vaccine. 

In addition, the company is vying to get FDA authorization for children 6 to 12 years old. The shot is already approved for that demographic in Europe, Canada and Australia. 

In addition, an interim analysis of a Phase 2 study of influenza vaccine candidate mRNA-1010 found no significant safety concerns. Furthermore, immunogenicity data from that trial indicate that the vaccine is potentially superior to a standard-dose vaccine for influenza A strains. 

Moderna has three mRNA-based influenza programs.  

The company announced earlier data related to mRNA-1010 in December that indicated that the performance of the quadrivalent seasonal flu vaccine candidate appeared to be roughly in line with the performance of Sanofi’s (Nasdaq:SNY) Fluzone HD flu vaccine.

Moderna also continues to work on several COVID-19 boosters, including omicron-specific and bivalent versions. A Phase 2 U.S. study for the former is fully enrolled while the latter continues to enroll participants. In the UK, a Phase 3 study is underway testing the omicron candidates as a third or fourth dose in fully vaccinated individuals. 

In addition, the company is developing a refrigerator-stable version of its COVID-19 vaccine known as mRNA-1283. 

Moderna continues to develop vaccines for respiratory syncytial virus (RSV) and is developing hybrid COVID-19/flu and COVID-19/flu/RSV vaccines.  

The company also is working on the vaccine candidate mRNA-1287 to protect against endemic human coronaviruses (HCoVs), which account for 10–30% of upper respiratory tract infections in adults. 

Finally, Moderna is developing vaccines to treat latent viruses, including Cytomegalovirus (CMV), Epstein-Barr virus (EBV), Varicella-Zoster virus (VZV), and herpes simplex virus (HSV). 

MRNA shares were up 0.12% to $178.95 in early afternoon trading. 


Filed Under: Infectious Disease
Tagged With: CMV, coronavirus, covid-19, COVID-19 boosters, COVID-19 vaccine, Epstein-Barr, flu, influenza, Moderna, RSV
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Pfizer-BioNTech
FDA allows booster dose Pfizer-BioNTech COVID-19 vaccine in children 5 to 11
AstraZeneca RQ Biotechnology
AstraZeneca paying up to $157M for broad-spectrum monoclonal antibodies against COVID
NIH National Institutes of Health
NIH licenses COVID-19 research technologies to WHO initiative
Olumiant
FDA approves Olumiant for treating some hospitalized COVID-19 patients

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • The Pharma 50